Impact of bile salts and a medium chain fatty acid on the physical properties of self-emulsifying drug delivery systems.

The aim of this study was the evaluation of the influence of bile salts and fatty acids, important components of intestinal fluids, on physical characteristics of self-emulsifying drug delivery systems (SEDDS) such as size, polydispersity (PDI), zeta potential (Zp), turbidity (T%), cloud point temperature (CPT) and drug release. At this purpose, nonionic (ni-SEDDS) and cationic (c-SEDDS) were emulsified in aqueous media containing increasing concentrations of bile salts (BS) and decanoate (Dec). Zp of ni-SEDDS and c-SEDDS became highly negative at 15 mM BS and Dec. Size of ni-SEDDS decreased of 112 nm and of 76 nm at 15 mM BS and Dec, respectively. Size of c-SEDDS decreased of 53 nm at 15 mM BS, but it was not affected by 15 mM Dec. PDI and T% of ni- and c-SEDDS were lowered as well. CPT of ni-SEDDS increased from 70 °C to 97 °C and 84 °C at 15 mM BS and Dec. CPT of c-SEDDS decreased from above 100 °C to 80 °C and to 85 °C at 1.5 mM BS and at 5 mM Dec, respectively. Generally, BS had a more pronounced effect on SEDDS Zp, size, PDI, T %, and CPT than Dec. The release of the model drug quinine was accelerated by BS and Dec. As BS and fatty acids affect the physical characteristics and drug release behavior of SEDDS, their impact should be addressed during the development process.

Zeta potential changing self-emulsifying drug delivery systems: A promising strategy to sequentially overcome mucus and epithelial barrier.

AIM: The aim of the present study was to develop zeta potential changing self-emulsifying drug delivery systems (SEDDS) via a flip-flop mechanism in order to improve their mucus permeating and cellular uptake properties. METHODS: Phosphorylated serine-oleylamine (p-Ser-OA) conjugates were synthesized and incorporated into SEDDS at a concentration of 1% (v/v). Cytotoxic potential of p-Ser-OA and p-Ser-OA loaded SEDDS was investigated on Caco-2 cells. Phosphate release was evaluated using isolated as well as cell-associated intestinal alkaline phosphatase (AP). In parallel, change in zeta potential and amino group concentration on the surface of SEDDS was determined. Furthermore, mucus permeation and cellular uptake studies were performed. RESULTS: p-Ser-OA was synthesized by covalent attachment of serine (Ser) to oleylamine (OA) via a carbodiimide-mediated reaction followed by phosphorylation using phosphorous pentoxide (P2O5) and phosphoric acid (H3PO4). The chemical structure of p-Ser-OA was confirmed via FT-IR, 1H NMR, 13C NMR, 31P NMR and mass spectroscopic analysis. p-Ser-OA loaded SEDDS exhibited a droplet size and zeta potential of 46.42 ±â€¯0.35 nm and -11.53 mV, respectively. A significant amount of phosphate was released after incubation with isolated as well as cell-associated AP within 6 h and zeta potential raised up to -2.04 mV. p-Ser-OA loaded SEDDS showed improved mucus permeation in comparison to p-Ser-OA loaded SEDDS treated with AP. Moreover, cellular uptake increased almost 2-fold after phosphate cleavage using AP. CONCLUSION: Findings of this study show that SEDDS changing their zeta potential via a flip-flop mechanism exhibit both high mucus permeating and high cellular uptake properties.

Self-emulsifying drug delivery systems: In vivo evaluation of their potential for oral vaccination.

Oral Immunization remains a challenge as antigens are rapidly metabolized in the gastrointestinal tract. In numerous previous studies, Self-emulsifying drug delivery systems (SEDDS) have demonstrated to be a promising tool for oral delivery of biologics. In this study, the potential of SEDDS as vehicle for oral vaccination has been evaluated. At this purpose, the model antigen Bovine serum albumin (BSA) has been incorporated in SEDDS after ion pairing. Squalane and monophosphoryl lipid A (MPLA) were chosen as adjuvants and dissolved in SEDDS containing BSA (SEDDS-BSA-squalane and SEDDS-BSA-MPLA). Formulations were administered orally to BALB/c mice. As control unformulated BSA was administrated orally (BSA-oral) and subcutaneously (BSA-sc). Systemic (anti BSA IgG titre) and mucosal (anti BSA IgA titre) immugenicity of BSA loaded in SEDDS and of unformulated BSA administered orally and subcutaneously was assessed and compared with each other. SEDDS-BSA-squalane and SEDDS-BSA-MPLA induced both higher anti BSA-IgG titre and anti BSA-IgA titre than orally administered unformulated BSA. BSA-sc induced the highest systemic immune response, however, the highest mucosal immune response was achieved via oral administration of SEDDS-BSA-squalane and SEDDS-BSA-MPLA. In general, SEDDS-BSA-MPLA showed the most promising systemic and mucosal immune response. According to these results, SEDDS seems to be a promising carrier for oral delivery of vaccines. STATEMENT OF SIGNIFICANCE: Oral vaccination is still a great challenge, as orally administered antigens are easily degraded in the gastrointestinal (GI) tract by peptidases and proteases. During the last years, self-emulsifying drug delivery systems (SEDDS) consisting of a mixture of oils and surfactants have been developed for the oral administration of hydrophilic macromolecular drugs. In this study, Bovine serum albumin (BSA) was chosen as model antigen and incorporated into self-emulsifying drug delivery systems (SEDDS) after hydrophobic ion pairing. Lipid A from Salmonella Minnesota R595 (MPLA) and squalane were chosen as adjuvants. SEDDS-BSA-MPLA and SEDDS-BSA-squalane were administered orally to mice. SEDDS-BSA-MPLA induced the strongest systemic (anti BSA-IgG titre) and mucosal (anti BSA-IgA titre) immune response. Based on these results, SEDDS are a promising alternative carrier for oral vaccine delivery.

Entirely S-Protected Thiolated Silicone: A Novel Hydrophobic Mucoadhesive and Skin Adhesive.

The aim of this study was the synthesis and evaluation of an entirely S-protected thiolated silicone as novel hydrophobic mucoadhesive and skin adhesive. 2-[(2-Amino-2-carboxyethyl)disulfanyl]nicotinic acid was covalently attached to a poly(dimethylsiloxane)-graft-polyacrylate via amide bond formation. Adhesive properties were determined via the rotating cylinder method and tensile studies on porcine small intestinal mucosa besides on porcine abdominal skin. Rheological characteristics were evaluated on a cone-plate rheometer. The S-protected thiolated silicone exhibited 128 ± 18 µmol immobilized 2-mercaptonicotinic acid per gram of polymer and showed a 5.9-fold extended time of mucosal adhesion compared with the unmodified silicone on the rotating cylinder. With a 2.3-fold higher maximum detachment force and a 1.7-fold higher total work of adhesion tested on porcine small intestinal mucosa, the S-protected thiolated silicone is superior to the unmodified silicone. Furthermore, using porcine abdominal skin, a 2.4-fold higher maximum detachment force and a 4.4-fold higher total work of adhesion obtained for the S-protected thiolated silicone outlines the preferentially adhesion to skin. Triggered by N-acetyl-L-cysteine liberated thiol groups form interchain and intrachain disulfide bonds within the polymer (6.7% m/v) causing a 23.0-fold increase in dynamic viscosity (ƞ). In parallel, the elastic modulus (G') and the viscous modulus (G") increased 39.2-fold and 8.1-fold, respectively.

In vitro evaluation of intravesical mucoadhesive self-emulsifying drug delivery systems.

Intravesical mucoadhesive self-emulsifying drug delivery system (SEDDS) have been developed via synthesis and incorporation of S-protected chitosan CS-MNA into SEDDS. N-acetyl cysteine-6-mercaptonicotinamide (NAC-6-MNA) was synthetized via disulphide exchange reaction between N-acetyl cysteine and 6-mercaptonicotinamide dimer. NAC-6-MNA was attached to chitosan (CS) via carbodiimide mediated amide bond formation. The S-protected chitosan (CS-MNA) and chitosan (CS) were complexed with sodium dodecyl sulfate (CS-SDS and CS-MNA-SDS) and incorporated in SEDDS at a concentration of 1% (m/m). SEDDS, SEDDS-CS-SDS and SEDDS-CS-MNA-SDS were characterized regarding size and zeta potential. 6-MNA release from SEDDS-CS-MNA-SDS in presence of glutathione was evaluated. Mucoadhesive properties of these novel formulations were assessed via rheology measurements and residence time evaluation on porcine bladder. Cytotoxicity of formulations was determined on porcine bladder. S-protected chitosan displayed 465.42 ±â€¯75.64 µmol of NAC-6-MNA per gram of polymer. SEDDS and SEDDS-CS-SDS and SEDDS-CS-MNA-SDS displayed a size of 22.5 ±â€¯0.9, 37.4 ±â€¯0.1 and 98.5 ±â€¯5.7 nm at a concentration of 20% (m/v) in simulated urine pH 6.2, and a zeta potential of -5.1 ±â€¯0.2, -1.6 ±â€¯0.1 and -1.4 ±â€¯0.2 mV at a concentration of 1% (m/v) in water at pH 6, respectively. 80% of MNA was released from SEDDS-CS-MNA-SDS in presence of glutathione. Viscosity of SEDDS-CS-SDS/mucus and SEDDS-CS-MNA-SDS/mucus was 6- and 18-fold higher than SEDDS/mucus after 90 min incubation. 2.6%, 5.8% and 14% of SEDDS, SEDDS-CS-SDS and SEDDS-CS-MNA-SDS remained on bladder mucosa within 120 min, respectively. No pronounced bladder cytotoxicity was observed in presence of 0.5% (m/v) formulations. According to these results, SEDDS-CS-MNA-SDS might be a promising carrier for intravesical drug administration.

Advanced formulations for intranasal delivery of biologics.

INTRODUCTION: The global biologics market has been ever increasing over the last decades and is predicted to top Euro 350 by 2020. Facing this scenario, the parenteral route of biologics administration as hitherto standard route is inconvenient for the future. Among the alternatives, the intranasal delivery of therapeutic biologicals seems to be most promising but researchers are still facing challenges as indicated by the scarce number of successfully marketed peptide drugs. AREAS COVERED: This review article is a compilation of current research focusing on achievements in the field of auxiliary agents for biologics delivery. First, the key benefits of the nose as most promising alternative route of drug administration are highlighted. Then, the potential of the different auxiliary agents in preclinical research is in detail discussed. Moreover, the most used permeation enhancing agents, mucolytic agents, mucoadhesive agents, in situ gelling agents and enzyme inhibiting agents in the formulation of nasal drug delivery systems are described. Thus, the overall purpose of this review is to highlight recent achievements in nasal delivery of biologics and to encourage researchers to work in the direction of needle-free nasal administration of biologics. EXPERT OPINION: The nasal epithelium is a promising route for biologics administration, which is reflected in a number of well-established products on the market treating chronic diseases as well as a large number of clinical trials currently in progress. The nasal route of drug administration might be a chance to improve therapy of biologics however break-through advances, especially for very complex molecules, such as antibodies, are still needed.

Glyceryl ester surfactants: Promising excipients to enhance the cell permeating properties of SEDDS.

AIM: The aim of the study is the evaluation of the impact of glyceryl ester surfactants on cell permeating properties of SEDDS (self-emulsifying drug delivery systems). METHODS: SEDDS containing the glyceryl ester surfactants polyglyceryl-3-stearate (TGlysurf9), polyglyceryl-5-oleate (TGlysurf11.5) and glyceryl stearate citrate (TGlysurf12) were prepared and characterized regarding droplet size and zeta potential. Toxicity studies were performed on Caco-2 cells using resazuring assay. The formulations were loaded with fluorescein diacetate (FDA) and curcumin, and cell uptake studies on Caco-2 cells were performed. Cell uptake was visualized via real time live confocal microscopy. Cell permeability of the SEDDS was tested and trans-epithelial electrical resistance (TEER) measurements were performed. Furthermore, the anti-proliferative and anti-migration activity of curcumin loaded in the SEEDS was investigated. RESULTS: The developed SEDDS (0.05% m/v) showed no cytotoxicity on Caco-2 cells after 3 h of incubation. Glyceryl esters-SEDDS showed a significant higher FDA and curcumin cell uptake than SEDDS without glyceryl ester surfactants (p < 0.05). TGlysurf9-SEDDS showed thereby the most pronounced permeation enhancing properties. TEER remained constant during the permeation study. Curcumin loaded in TGlysurf9-SEDDS exhibited 1.9-fold higher anti-proliferative effect than curcumin loaded in SEDDS without glyceryl ester surfactants. Furthermore, curcumin loaded in glyceryl ester-SEDDS inhibited Caco-2 cells migration to a higher extent than unloaded curcumin and curcumin loaded in SEDDS without the glyceryl ester surfactants. CONCLUSIONS: Glyceryl ester surfactants and in particular polyglyceryl-3-stearate might be a promising excipient for the formulation of SEDDS exhibiting enhanced cellular uptake and permeation enhancing properties.

Anhydrous thiomers: Strategy for enhanced mucoadhesion.

AIM: The aim of this study was to evaluate the impact of the absence of water during the synthesis of thiolated poly(acrylic acid) (PAA) on its mucoadhesive properties. Previously, thiolation of hydrophilic polymers was performed in aqueous media, where (poly)acrylates undergo a conformational transition to form an entangled network of polymer chains stabilized by neutralization. The impact of chain entanglement, porosity and degree of functionalization of anhydrous precipitated polymers on their mucoadhesive characteristics were therefore evaluated in comparison to the equivalent products synthesized in water and dried by lyophilization. METHODS: Anhydrous synthesis and purification procedures were designed for the thiolation and entire preactivation of PAA by means of immobilization of l-cysteine (PAA-Cys) and 2-mercaptonicotinic acid (PAA-Cys-MNA), respectively. The obtained conjugates were characterized chemically and for their particle size. Differences in mucoadhesive properties were determined by means of the residence time as well as tensile strength of polymer test disks on porcine small intestinal mucosa. RESULTS: Anhydrous products revealed a 4.2-fold higher amount of immobilized free thiol moieties for PAA-Cys and a 3.1-fold higher quantity of 2-mercaptonicotinic acid for PAA-Cys-MNA. The impact of particle size of anhydrous products on their mucoadhesive properties was negligible. In comparison to the corresponding aqueous products a 2.5-fold increase in residence time for PAA-Cys and 21.2-fold increase for PAA-Cys-MNA was achieved and in agreement with these results, the improvement in the total work of adhesion was 2.9-fold for PAA-Cys and 5.1-fold for PAA-Cys-MNA. CONCLUSION: According to these findings, anhydrous synthesis conditions seem to be a promising tool for improved modification rates and moreover enhanced mucoadhesive properties of hydrophilic polymers.

Mucoadhesive self-emulsifying delivery systems for ocular administration of econazole.

AIM: Development of mucoadhesive self-emulsifying drug delivery systems (SEDDS) providing a prolonged ocular residence time for poorly soluble active pharmaceutical ingredient. METHODS: l-Cysteine was covalently linked to 6-mercaptonicotinamide. The obtained ligand, Cysteine-6-mercaptonicotinamide (Cys-6-MNA) was attached to Eudragit® L100-55 via a carbodiimide mediated amide bond formation. The resulting entirely S-protected thiolated Eudragit® L100-55 was characterized regarding the degree of modification as well as stability toward oxidation in the presence of strong oxidizing agent (H2O2). The S-protected thiolated Eudragit® L100-55 was incorporated into SEDDS via hydrophobic ion pairing with benzalkonium chloride (BAK) in a concentration of 2% (m/m). S-protected thiolated Eudragit® L100-55-BAK ion pair SEDDS (S-protected thiolated EU-BAK SEDDS) were characterized regarding their physicochemical and mucoadhesive properties. Econazole nitrate (EN) was incorporated into SEDDS in concentration of 1% (m/m) and in vitro drug release was assessed. Furthermore, toxicity study was performed on procine corneas via resazurin assay. RESULTS: The entirely S-protected thiolated Eudragit® L100-55 exhibited 282 ±â€¯78.25 µmol of MNA per gram of polymer. Ellman's test confirmed no free thiol groups and stability study showed no significant increase in dynamic viscosity overtime. The droplet size of developed SEDDS in simulated lacrimal fluid was below 100 nm with polydispersity index below 0.3. S-protected thiolated EU-BAK SEDDS exhibited 2.5-fold higher mucoadhesive properties than blank SEDDS on ocular mucosa. S-protected thiolated EU-BAK SEDDS showed sustained EN release over period of 8 h and no pronounced corneal toxicity in 0.5% (m/v) concentration. CONCLUSION: Accordingly, these mucoadhesive SEDDS can be considered as promising ocular delivery system for EN.

Development of pre-activated α-cyclodextrin as a mucoadhesive excipient for intra-vesical drug delivery.

The study was designed to synthesize and characterize pre-activated α-cyclodextrin (α-CD) derivatives as mucus adhering excipients for intra-vesical drug delivery. Sodium periodate (NaIO4) was used to oxidize α-CD and subsequently cysteamine was covalently attached to carbonyl groups of oxidized α-CD via reductive amination to produce thiolated α-CD. l-cysteine-2-mercaptonicotinic acid conjugate (Cys-MNA) was covalently attached to carbonyl groups of oxidized α-CD to produce pre-activated α-CD having enhance stability against oxidation at higher pH. Thiolated and pre-activated α-CD derivatives were quantitatively assayed for the attached thiol groups and MNA groups, respectively. Cell viability and tolerability was evaluated via resazurin assay and via red blood cells (RBC) lysis assay, respectively. Mucoadhesive properties were evaluated on porcine bladder mucosa. Trimethoprim (TMP) was encapsulated into thiolated and pre-activated α-CD derivatives and the dissolution behavior was evaluated in vitro. Thiol groups attached to thiolated α-CD derivatives α-CD-SH780 and α-CD-SH1426 were 780±68µmol/g and 1426±66µmol/g, respectively. For the entirely pre-activated α-CD derivatives, α-CD-MNA3609 and α-CD-MNA4285 number of attached MNA groups were 3609±19µmol/g and 4285±43µmol/g, respectively. Thiolated and pre-activated derivatives of α-CD did not show adverse effects to cells determined via resazurin and RBC lysis assays. Mucoadhesion on porcine bladder mucosa was significantly improved for thiolated and pre-activated α-CD derivatives. Thiolated α-CD-SH1426 showed 15-fold and pre-activated α-CD-MNA4285 showed 25-fold improved mucoadhesion compared to unmodified α-CD. Further, pre-activated α-CD-MNA4285 showed 2-fold enhanced dissolution of encapsulated TMP compared to free TMP over 3 h. The study shows that pre-activated α-CD could be an excipient of the choice for the formulations of mucoadhesive intra-vesical drug delivery systems.

Entirely S-protected chitosan: A promising mucoadhesive excipient for metronidazole vaginal tablets.

AIM: Synthesis and evaluation of an entirely S-protected chitosan as mucoadhesive excipient for vaginal drug delivery. METHODS: N-acetyl-cysteine was linked to 6-mercaptonicotinamide via disulphide exchange reaction. The obtained ligand, NAC-6-MNA, was subsequently attached to chitosan by carbodiimide mediated amide bond formation in two concentrations. The synthesized S-protected chitosan was chemically characterized and mucoadhesive properties and stability against oxidation were investigated. Moreover, metronidazole tablets comprising the S-protected chitosan were evaluated regarding water uptake capacity, disintegration behaviour, residence time on vaginal mucosa, release of the encapsulated drug and antimicrobial activity. RESULTS: S-protected chitosan displayed 160±19 (CS-MNA-160) and 320±38 (CS-MNA-320)µmol of ligand per gram of polymer. At pH 4.2, CS-MNA-160 and CS-MNA-320 showed 5.2-fold and 6.2-fold increase in mucus viscosity in comparison to unmodified chitosan (One-way ANOVA, p<.001), whereas, 9.9-fold (CS-MNA-160) and 15.6-fold (CS-MNA-320) (One-way ANOVA, p<.001) increase in viscosity was measured at pH 6. The S-protected chitosan remained stable against oxidation in presence of 0.5%v/v hydrogen peroxide. Metronidazole tablets consisting in S-protected chitosan showed prolonged residence time on vaginal mucosa and improved water uptake capacity and disintegration time in comparison to tablets consisting of unmodified chitosan. Moreover, CS-MNA-320 metronidazole tablets displayed prolonged drug release and antimicrobial activity. CONCLUSIONS: On the basis of the achieved results, entirely S-protected chitosan represents a promising excipient for the development of metronidazole vaginal tablets. STATEMENT OF SIGNIFICANCE: S-protected thiomers are polymers modified with thiol groups protected by aromatic ligands and characterized by strong mucoadhesive properties and high stability against oxidation. Up to date, the entirely S-protection of thiol groups was achieved via the synthesis of the ligand 2-((2-amino-2-carboxyethyl)disulfanyl)nicotinic acid) which can be directly bound to the backbone of polymers bearing carboxylic moieties as pectin. However, this ligand is not suitable for positively charged polymers due to the negative charge. In this paper, the synthesis of a suitable ligand for the entirely S-protection of positively charged polymers is presented. The first entirely S-protected chitosan was synthesized, characterized and its mucoadhesive properties were assessed. Moreover, metronidazole tablets comprising the entirely S-protected chitosan were developed and evaluated as vaginal drug delivery system.

Inhibitory effect of emulsifiers in sedds on protease activity: Just an illusion?

AIM: Evaluation of inhibitory effect of emulsifiers on pancreatic trypsin and α-chymotrypsin. METHODS: The inhibitory effect of Cremophor EL, Cremophor RH 40, Brij O10, Tween 20, polyethylene glycol 8000, polyethylene glycol 400, Carbitol, Pemulen TR-1, Pemulen TR-2, Carbopol Ultrez 20 and Carbopol Ultrez 21 on pancreatic trypsin and α-chymotrypsin was tested. BAEE (Nα-Benzoyl-l-arginine ethyl ester), BTEE (N-Benzoyl-l-tyrosine ethyl ester), casein and insulin were used as substrates for trypsin and α-chymotrypsin. SEDDS containing Pemulen TR-2 were developed, loaded with insulin-DMPG (dimyristoylphosphatidylglycerol) complex, characterized and tested regarding the protective effect towards the proteolytic degradation of insulin. RESULTS: Cremophor EL, Cremophor RH 40, Brij O10, Tween 20, polyethylene glycol 8000, polyethylene glycol 400, Carbitol did not show any inhibitory effect towards trypsin and α-chymotrypsin, whereas Pemulen TR-1, Pemulen TR-2, Carbopol Ultrez 20 and Carbopol Ultrez 21 inhibited the enzymes in a concentration dependent manner. Moreover, Pemulen and Carbopol Ultrez emulsifiers exhibited comparable inhibitory properties (p>0.05). The incorporation of 0.34% w/w of Pemulen TR-2 in SEDDS decreased the degradation rate of the loaded insulin-DMPG complex compared to the blank formulation (p<0.05). CONCLUSION: The present study revealed that commonly used emulsifiers in SEDDS do not have inhibitory properties on the proteolytic activity of trypsin and α-chymotrypsin. Moreover, it was demonstrated that the incorporation of emulsifiers with inhibitory properties towards trypsin and α-chymotrypsin in SEDDS play a minor role in the protection of embedded drugs from enzymatic degradation.

Design, modification and in vitro evaluation of pectin's bucco-adhesiveness.

AIM: It was the aim of this study to synthesize pectin (PEC) with sulfhydryl groups and evaluate its suitability in buccal application. MATERIALS & METHODS: Native PEC was chemically modified by covalent attachment of sulfhydryl-bearing cysteine (CYS). Stability assays in form of water uptake behavior and erosion study were performed. Additionally, mucoadhesive study on buccal mucosa was performed. RESULTS: Pectin-cysteine (PECCYS) was successfully synthesized as proved by IR and Ellman's assay exhibiting 436.59 ± 127.87 µmol thiol groups per gram polymer. Stability assay showed that PECCYS revealed a 2.27-fold improved water uptake and mucoadhesiveness augmented 3.75-fold in comparison to unmodified PEC. CONCLUSION: PECCYS might be a future suitable excipient for buccal adhesive application.